Advertisement

November 19, 2026

Burl Concepts’ Foqus Ultrasound System Cleared for PFO Screening

KEY TAKEAWAYS

  • The FDA granted 510(k) clearance to Burl Concepts’ Foqus ultrasound system for detecting transient cerebral embolic signals.
  • The automated transcranial ultrasound system evaluates the whole brain in 40 seconds and is intended to support right-to-left shunt screening.
  • Burl Concepts plans an initial United States commercial launch in early 2027, targeting cardiology practices and outpatient diagnostic centers.

November 19, 2026—Burl Concepts, a developer of an automated test for evaluating cerebral blood flow and rapid detection of emboli, announced that the FDA has granted 510(k) clearance for the Foqus ultrasound system, powered by the company’s Sonas, which monitors the entire brain for the appearance of emboli.

Burl Concepts advised that the first clinical application of Foqus will be a standard “bubble test” for patent foramen ovale (PFO) to help identify the presence of a right-to-left shunt. The company is preparing for the Foqus system’s initial United States commercial launch with a focus on cardiology practices and outpatient diagnostic centers in early 2027.

The company stated that the portable, automated Foqus transcranial ultrasound system is indicated for use for measuring the occurrence of transient embolic signals in the brain blood stream.

The system uses low-energy, low-frequency ultrasound to penetrate the skull and evaluate the whole brain in 40 seconds, detecting acoustic signals from the entire circulation, including both macro and microvasculature. The test can be performed by a single nurse in physician offices, diagnostic centers, or hospitals.

“Identifying a PFO in a patient who has had a cryptogenic stroke is a critical step toward preventing the next one,” commented Matthew J. Price, MD, in the company’s press release. “Foqus gives us a simple, objective test that evaluates the whole brain without the need to find a specific acoustic window or vessel. FDA clearance means physicians in the United States can bring Foqus to more patients, sooner. It has the potential to disrupt the way we currently diagnose PFOs.”

Dr. Price is Professor of Medicine and Director, Cardiac Catheterization Laboratory at the Scripps Clinic in La Jolla, California.

Foqus is also being used in the Netherlands and the United Kingdom, where early experience has included the detection of embolic signals associated with right-to-left shunting. Additional clinical trials in the United States and Europe are underway, stated Burl Concepts.

Advertisement


November 19, 2026

VOYAGER CE Begins for Abbott’s Encantor Software-Guided Balloon-Expandable TAVR System

November 19, 2026

FDA Clears Siemens Healthineers Syngo.CT Coronary Cockpit Software


)